文献速递流行病学与生物统计真实世界研究与卫生经济

2型糖尿病降糖治疗随机对照试验中的衰弱:衰弱患病率、疗效与不良事件的个体参与者数据荟萃分析

Frailty in randomized controlled trials of glucose-lowering therapies for type 2 diabetes: An individual participant data meta-analysis of frailty prevalence, treatment efficacy, and adverse events.
PubMed 文献 · PLoS Med · 2025-04-07

该研究利用34项SGLT2抑制剂、GLP1受体激动剂和DPP4抑制剂试验的25208例个体参与者数据,以累积缺陷衰弱指数(FI)量化衰弱。FI>0.2的衰弱中位患病率为9.5%,FI>0.3为0.5%;FI每增加0.1,HbA1c降幅小幅减弱且低于临床意义水平,全因不良事件、严重不良事件、低血糖、MACE基线风险和退出试验的风险均升高。

要点

  • FI>0.2的衰弱中位患病率为9.5%(IQR 2.4%-15.4%),FI>0.3为0.5%(IQR 0.1%-1.5%)。
  • FI每增加0.1,SGLT2抑制剂和GLP1受体激动剂的HbA1c降幅分别减小0.08和0.14个百分点,低于临床意义水平。
  • FI每增加0.1与全因不良事件(IRR 1.44,95%CI 1.35-1.54)、严重不良事件(IRR 2.09,95%CI 1.85-2.36)和退出试验(OR 1.41,95%CI 1.27-1.57)风险升高相关。

核心结论

  • 衰弱在这些试验中不常见,高度衰弱的参与者很少被纳入。
  • 衰弱与血糖结局疗效的非常轻微减弱相关,并与不良事件和MACE发生率升高相关,且独立于治疗分配。
  • 这些发现与对衰弱人群放宽HbA1c目标的呼吁相符,同时也凸显将衰弱人群纳入试验的必要性。
  • 由于高度衰弱者大多被排除在试验之外,其绝对风险与获益平衡仍不确定。

研究设计与样本

  • 研究分析了34项SGLT2抑制剂、GLP1受体激动剂和DPP4抑制剂试验的个体参与者数据,共25208例参与者。
  • 采用累积缺陷衰弱指数(FI)量化衰弱,并评估衰弱与治疗疗效(HbA1c和主要不良心血管事件[MACE],采用随机效应网络荟萃分析合并)及不良事件之间的关联。
  • 纳入试验的平均年龄范围为53.8至74.2岁。

主要发现

  • 以FI>0.2为衰弱切点时,中位患病率为9.5%(IQR 2.4%-15.4%);以FI>0.3为切点时,中位患病率为0.5%(IQR 0.1%-1.5%)。
  • 在老年人和肾功能受损者的试验中患病率更高,但即使在这些高风险人群中,FI>0.4者通常也不存在。
  • 对于SGLT2抑制剂和GLP1受体激动剂,随着衰弱增加,HbA1c降幅分别减小0.08和0.14个百分点(FI每增加0.1),低于临床意义水平。
  • 治疗对MACE的影响(以及是否因衰弱而异)存在高度不确定性,试验随访期间发生的事件很少。
  • FI每增加0.1与全因不良事件(IRR 1.44,95%CI 1.35-1.54,p<0.0001)、判定为可能或很可能与治疗相关的不良事件(IRR 1.36,95%CI 1.23-1.49,p<0.0001)、严重不良事件(IRR 2.09,95%CI 1.85-2.36,p<0.0001)、低血糖(IRR 1.21,95%CI 1.06-1.38,p=0.012)、MACE基线风险(HR 3.01,95%CI 2.48-3.67,p<0.0001)和退出试验(OR 1.41,95%CI 1.27-1.57,p<0.0001)相关,且与治疗分配无关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 主要局限性是大型心血管结局试验未纳入功能状态数据,因此无法在这些更大规模的试验中评估衰弱。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The representation of frailty in type 2 diabetes trials is unclear. This study used individual participant data from trials of newer glucose-lowering therapies to quantify frailty and assess the association between frailty and efficacy and adverse events. METHODS AND FINDINGS: We analysed IPD from 34 trials of sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP1) receptor agonists, and dipeptidyl peptidase 4 (DDP4) inhibitors. Frailty was quantified using a cumulative deficit frailty index (FI). For each trial, we quantified the distribution of frailty; assessed interactions between frailty and treatment efficacy (HbA1c and major adverse cardiovascular events [MACE], pooled using random-effects network meta-analysis); and associations between frailty and withdrawal, adverse events, and hypoglycaemic episodes. Trial participants numbered 25,208. Mean age across the included trials ranged from 53.8 to 74.2 years. Using a cut-off of FI > 0.2 to indicate frailty, median prevalence was 9.5% (IQR 2.4%-15.4%). Applying a higher threshold of FI > 0.3, median prevalence was 0.5% (IQR 0.1%-1.5%). Prevalence was higher in trials of older people and people with renal impairment however, even in these higher risk populations, people with FI > 0.4 were generally absent. For SGLT2 inhibitors and GLP1 receptor agonists, there was a small attenuation in efficacy on HbA1c with increasing frailty (0.08%-point and 0.14%-point smaller reduction, respectively, per 0.1-point increase in FI), below the level of clinical significance. Findings for the effect of treatment on MACE (and whether this varied by frailty) had high uncertainty, with few events occurring in trial follow-up. A 0.1-point increase in the FI was associated with more all-cause adverse events regardless of treatment allocation (incidence rate ratio, IRR 1.44, 95% CI 1.35-1.54, p < 0.0001), adverse events judged to the possibly or probably related to treatment (1.36, 1.23, to 1.49, p < 0.0001), serious adverse events (2.09, 1.85, to 2.36, p < 0.0001), hypoglycaemia (1.21, 1.06, to 1.38, p = 0.012), baseline risk of MACE (hazard ratio 3.01, 2.48, to 3.67, p < 0.0001) and with withdrawal from the trial (odds ratio 1.41, 1.27, to 1.57, p < 0.0001). The main limitation was that the large cardiovascular outcome trials did not include data on functional status and so we were unable to assess frailty in these larger trials. CONCLUSIONS: Frailty was uncommon in these trials, and participants with a high degree of frailty were rarely included. Frailty is associated very modest attenuation of treatment efficacy for glycaemic outcomes and with greater incidence of both adverse events and MACE independent of treatment allocation. While these findings are compatible with calls to relax HbA1c-based targets in people living with frailty, they also highlight the need for inclusion of people living with frailty in trials. This would require changes to trial processes to facilitate the explicit assessment of frailty and support the participation of people living with frailty. Such changes are important as the absolute balance of risks and benefits remains uncertain among those with higher degrees of frailty, who are largely excluded from trials.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Wightman H, Butterly E, Wei L, et al. Frailty in randomized controlled trials of glucose-lowering therapies for type 2 diabetes: An individual participant data meta-analysis of frailty prevalence, treatment efficacy, and adverse events. PLoS Med. 2025. PMID: 40193407. doi:10.1371/journal.pmed.1004553

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。